In non-small-cell lung cancer (NSCLC), Baylin and colleagues showed that in vitro combinatorial treatment of HDACi and DNMTi resulted in the suppression of MYC signaling, as well as the induction of Type I IFN pathway related genes and antigen presentation genes [54]. Here, MYC is linked to non-small cell lung carcinoma.